RxDoctor Payments Data

Todd Maltese, DO

Neurology · Ronkonkoma, NYNPI 1255521456

Payments from drug & device makers

$43,003in general payments, 2019–2025

Across 1,038 payments — averaging $41.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$21K
  • Teva Pharmaceuticals USA, Inc.$3K
  • Harmony Biosciences LLC$2K
  • UCB, Inc.$2K
  • Biogen$1K
  • Livanova USA, Inc.$1K
  • plus $13K from 54 others

What the payments were for

  • Speaking & faculty fees$17,23040%
  • Travel & lodging$8012%
  • Food & beverage$24,55257%
  • Education$4201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)194$21,461
Teva Pharmaceuticals USA, Inc.94$2,753
Harmony Biosciences LLC48$1,906
UCB, Inc.72$1,531
Biogen68$1,394
Livanova USA, Inc.6$1,053
Jazz Pharmaceuticals Inc.30$936
Scilex Pharmaceuticals Inc.42$839
Lundbeck LLC44$782
Lilly USA, LLC31$766
Sanofi29$678
Pfizer33$677
Amneal Pharmaceuticals LLC25$590
SK Life Science, Inc.11$589
Novartis27$538
Acorda Therapeutics, Inc22$504
Amgen(2 entities)25$479
Axsome Therapeutics, Inc.13$466
Supernus Pharmaceuticals, Inc.22$463
EMD Serono, Inc.23$401
Biohaven Pharmaceutical Holding Company Ltd.16$399
Medtronic(2 entities)5$364
Argenx US, Inc.12$341
Sunovion Pharmaceuticals Inc.9$307
Neurocrine Biosciences, Inc.10$279
Upsher-smith Laboratories LLC14$251
Idorsia Pharmaceuticals US Inc11$200
Merck12$198
Azurity Pharmaceuticals, Inc.10$165
Inspire Medical Systems, Inc.5$165
Biohaven Pharmaceuticals, Inc.6$153
AstraZeneca6$140
Promius Pharma LLC3$123
Arbor Pharmaceuticals, Inc.8$107
Almatica Pharma LLC5$104
Genentech USA, Inc.5$80
Bristol Myers Squibb4$80
Bausch Health US, LLC4$72
Currax Pharmaceuticals LLC4$65
E.r. Squibb & Sons, L.L.C.4$60
Tanabe Pharma America, Inc.2$55
Assertio Therapeutics, Inc.3$51
Kyowa Kirin, Inc.2$50
Neuronetics, Inc.2$49
Impel Pharmaceuticals Inc.2$30
Averitas Pharma Inc.1$27
Neurelis, Inc.1$26
Zyla Life Sciences, Inc.1$24
Boston Scientific1$24
Forte Bio-pharma LLC1$23
Valinor Pharma, LLC1$22
Tonix Medicines, Inc.1$21
GRT US Holding, Inc.1$20
Avanir Pharmaceuticals, Inc.1$19
Grifols USA, LLC1$19
Banner Life Sciences, LLC1$18
Collegium Pharmaceutical, Inc.1$17
Alfasigma USA, Inc.1$16
GE HealthCare1$16
ZOLL Respicardia, Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$43,003 in reported general payments places this provider in the 80th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$409,254
Medicare patients
359
Services billed
18,778

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
InbrijaLevodopa11$26,330
LamictalLamotrigine12$19,618
LyricaPregabalin13$7,728
Carbidopa-LevodopaCarbidopa/Levodopa18$668
Memantine Hcl14$360
Divalproex Sodium17$317
Gabapentin16$307
Topiramate19$239
Primidone13$216
Donepezil Hcl13$135
Lamotrigine12$74
Trazodone Hcl18$50

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acorda Therapeutics, IncInbrija$504$26,33011 claims
PfizerLyrica$677$7,72813 claims
Upsher-smith Laboratories LLCTopiramate$251$23919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,623 neurology providers in New York.

Other neurology in Ronkonkoma

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →